Merck & Co. Inc.

87.53
1.93 (2.25%)
At close: Feb 20, 2025, 3:58 PM
87.62
0.10%
After-hours: Feb 20, 2025, 06:05 PM EST

Company Description

Merck & Co., Inc. operates as a healthcare company worldwide.

It operates through two segments, Pharmaceutical and Animal Health.

The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV.

Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co. Inc.
Merck & Co. Inc. logo
Country United States
IPO Date Jan 13, 1978
Industry Drug Manufacturers - General
Sector Healthcare
Employees 70,000
CEO Robert M. Davis J.D.

Contact Details

Address:
2000 Galloping Hill Road
Kenilworth, New Jersey
United States
Website https://www.merck.com

Stock Details

Ticker Symbol MRK
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000310158
CUSIP Number 58933Y105
ISIN Number US58933Y1055
Employer ID 22-1918501
SIC Code 2834

Key Executives

Name Position
Robert M. Davis J.D. Chairman, President & Chief Executive Officer
Caroline Litchfield Executive Vice President & Chief Financial Officer
Cristal N. Downing Executive Vice President and Chief Communications & Public Affairs Officer
Dalton E. Smart III Senior Vice President of Finance, Principal Accounting Officer & Global Controller
David Michael Williams Executive Vice President and Chief Information & Digital Officer
Dr. Dean Y. Li M.D., Ph.D. Executive Vice President & President of Merck Research Laboratories
Jennifer L. Zachary J.D. Executive Vice President & General Counsel
Peter Dannenbaum Vice President of Investor Relations
Richard R. DeLuca Jr. Executive Vice President & President of Merck Animal Health
Sanat Chattopadhyay Executive Vice President & President of Merck Manufacturing Division

Latest SEC Filings

Date Type Title
Feb 14, 2025 13F-HR Quarterly report filed by institutional managers, ...
Feb 13, 2025 4 Filing
Feb 11, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 04, 2025 8-K Current Report
Feb 03, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 29, 2025 4 Filing
Jan 29, 2025 4 Filing